Hematology, Oncology and Tumor Immunology, and *Labor Berlin, Hematology - Tumor Genetics, Berlin, Germany. E-mail: margitta.worm@charite.de.

*Shared first authorship.

The Anaphylaxis Registry was supported by the Network for Online-Registration of Anaphylaxis NORA e. V. T.B. was supported by the Deutsche José Carreras Leukämie-Stiftung e. V.

Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.

REFERENCES

1. Nassiri M, Eckermann O, Babina M, Edenharter G, Worm M. Serum levels of 9alpha,11beta-PGF2 and cysteinyl leukotrienes are useful biomarkers of anaphylaxis. J Allergy Clin Immunol 2016;137:312-4. e7.

2. Rueff F, Przybilla B, Bilo MB, Muller U, Scheip F, Aberer W, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase—a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009;124:1047-54.

3. Valent P, Akin C, Bonadonna P, Hartmann K, Brockow K, Niedoszytko M, et al. Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. J Allergy Clin Immunol Pract 2019;7:1125-33. e1.

4. Worm M, Francuzik W, Renaudin JM, Bilo MB, Cardona V, Scherer Hofmeier K, et al. Factors increasing the risk for a severe reaction in anaphylaxis: an analysis of data from The European Anaphylaxis Registry. Allergy 2018;73:1322-30.

5. Valent P, Escribano L, Broesby-Olsen S, Vestergaard H, Moller MB, Siebenhaar F, et al. Recognizing mastocytosis in patients with anaphylaxis: value of KIT D816V mutation analysis of peripheral blood. J Allergy Clin Immunol 2015;135:262-4.

6. Broesby-Olsen S, Oroppeza AR, Bindslev-Jensen C, Vestergaard H, Moller MB, Siebenhaar F, et al. Factors increasing the risk for a severe reaction in anaphylaxis: an analysis of data from The European Anaphylaxis Registry. Allergy 2018;73:1322-30.

7. Valent P, Escribano L, Broesby-Olsen S, Vestergaard H, Moller MB, Siebenhaar F, et al. Recognizing mastocytosis in patients with anaphylaxis: value of KIT D816V mutation analysis of peripheral blood. J Allergy Clin Immunol 2015;135:262-4.

8. Broesby-Olsen S, Oroppeza AR, Bindslev-Jensen C, Vestergaard H, Moller MB, Siebenhaar F, et al. Patterns of anaphylaxis after diagnostic workup: a follow-up study of 226 patients with suspected anaphylaxis. Allergy 2017;72:1944-52.

9. Carter MC, Bai Y, Ruiz-Esteses KN, Scott LM, Cantave D, Bolan H, et al. Detection of KIT D816V in peripheral blood of children with manifestations of cutaneous mastocytosis suggests systemic disease. Br J Haematol 2018;183:775-82.

Available online August 12, 2019. https://doi.org/10.1016/j.jaci.2019.07.037

A comprehensive characterization of chronic norovirus infection in immunodeficient hosts

To the Editor:

Chronic norovirus infection (CNI) can be devastating in patients with immunodeficiency.1 We sought to investigate immunologic and virologic factors associated with chronic infection and document outcomes from a structured treatment algorithm.

We identified 10 patients with CNI (1 referred from Oxford University Hospitals), which was defined as compatible symptoms (diarrhea, weight loss, and vomiting) or malabsorption with stool samples with positive PCR results for norovirus for more than 3 months. We also recruited control groups (see the Methods section in this article’s Online Repository at www.jacionline.org).

Nine patients had CVID, and 1 had chronic lymphocytic leukemia and secondary antibody deficiency. Comorbidities and concurrent infections are detailed in Table E1 in this article’s Online Repository at www.jacionline.org.

and CD19<sup>+</sup> values for 8 patients with CVID with CNI versus 113 patients with CVID without CNI. Lines represent medians. P values are from Mann-Whitney tests.

FIG 1. Long-term average (from 2000 [or date of CVID diagnosis, if later] to 2018) CD3<sup>+</sup> and CD19<sup>+</sup> values for 8 patients with CVID with CNI versus 113 patients with CVID without CNI. Lines represent medians. P values are from Mann-Whitney tests.

Available online August 12, 2019. https://doi.org/10.1016/j.jaci.2019.07.037

FIG 1. Long-term average (from 2000 [or date of CVID diagnosis, if later] to 2018) CD3<sup>+</sup> and CD19<sup>+</sup> values for 8 patients with CVID with CNI versus 113 patients with CVID without CNI. Lines represent medians. P values are from Mann-Whitney tests.
because of a subsequent increase in CD21− B-cell counts). T-cell proliferation with 8 μg/mL PHA was impaired in all patients (median, 8.1% [5.2% in 6 patients undergoing immunosuppression and 9.5% in 4 patients off immunosuppression]; range, 0.5% to 33.7% of contemporaneous control; see Table E2 in this article’s Online Repository at www.jacionline.org). In 7 of 8 patients, we observed a possible temporal relationship between decreasing CD3+ and CD19+ cell counts and diagnosis or earliest date of norovirus acquisition (see Fig E1 in this article’s Online Repository at www.jacionline.org). Often this correlated with iatrogenic immunosuppression for inflammatory or autoimmune disease: 2 patients received high-dose corticosteroids, and 1 received corticosteroids and rituximab. The patient from Oxford University Hospitals was receiving prednisolone and mycophenolate mofetil at diagnosis. Four patients (D, E, I, and J) received corticosteroids with or without infliximab for “CVID enteropathy” before norovirus diagnosis.

We further characterized peripheral blood lymphocytes in patients with CVID through flow cytometry. Versus healthy control subjects, patients with CNI had significantly reduced CD27+ B-cell counts, including switched memory cells and CD80+ and CXCR5+ B-cell percentages but increased CD21− (of which 68.6% were CXCR5+) and transitional B-cell percentages (see Fig E2, A). In patients with CVID without norovirus also demonstrated increased follicular helper T-cell counts but not total PD-1+ CD4+ T-cell percentages.

Norovirus-infected patients had significantly increased numbers of CD4+ follicular helper T (CXCR5+PD1+) cells (9.5% ± 6.3% of total CD4+ T cells) and overall programmed cell death protein 1 (PD-1)+CD4+ cells (36.7% ± 22.4% of total CD4+ T cells), with a trend toward decreased naive (CD45RA−CD62L+) cell percentages versus control subjects (see Fig E2, A). Patients with CVID without norovirus also demonstrated increased follicular helper T-cell counts but not total PD-1+ CD4+ T-cell percentages.

Table E2 in this article’s Online Repository at www.jacionline.org summarizes gastrointestinal findings. Duodenal biopsy specimens demonstrated villous atrophy and intraepithelial lymphocytosis in 7 patients (see Fig E3, A, in this article’s Online Repository at www.jacionline.org); both patients with “normal” duodenal histology had profound small bowel villous atrophy observed endoscopically (see Fig E3, B). Therefore all 9 patients with mucosal assessment had macroscopic or histologic evidence of villous atrophy.

Immunohistochemical staining in 6 biopsy specimens revealed increased intraepithelial CD3+ lymphocytes, predominantly CD8+. CD4+ lymphocyte frequencies varied. Patients with CVID had absent or severely reduced numbers of CD19+ lymphocytes. All patients had granzyme B–positive cells, with perforin staining in 3: their distribution was identical to CD8+ T cells, suggesting that epithelial cell injury is mediated in part by cytotoxic cells.

We performed norovirus whole-genome sequencing to exclude cross-transmission. Patient sample consensus sequences were used with worldwide surveillance reference strains to construct phylogenetic trees (see Fig E4 in this article’s Online Repository at www.jacionline.org). Patients A, B, and E were...
infected with the GII.4 variant New Orleans 2009, and patients D and J were infected with viruses clustering between GII.4 US95/96 and GII.4 Osaka 2007, but the viruses separated in the trees (see Fig E5 in this article’s Online Repository at www.jacionline.org). Other patients were infected with distinct genotypes or variants (see Table E3 in this article’s Online Repository at www.jacionline.org), and therefore no evidence supported transmission within the cohort.

We estimated patient-specific infection intervals by calculating divergence and ancestor dates (see Table E3). Patient F was likely infected within the 5 months before diagnosis, but intervals for other patients suggested years of antecedent infection. Sequencing also demonstrated relapses with the same strain after long periods of negative PCR results (up to 11 months in patient E [see below] and 14 months in patient F), which was far longer than has been described previously.1

Viral diversity (number of nucleotide differences between reads at a specific site)2 was extremely high in our cohort compared with that in the control groups (see Fig E6, A, in this article’s Online Repository at www.jacionline.org). This diversity is rapidly generated, for example, in patient A within 6 months of the most recent common ancestor (see Fig E6, B) and then fluctuates over time (see Fig E6, C). The diversity within patient C, whose virus had GILP7 RdRp, was lower than in those with GILP4 RdRp, which is consistent with a lower mutation rate with the GILP7 polymerase.3 Diversity or estimated infection duration did not correlate with drug treatment outcome, but notably, only patient C has achieved sustained viral clearance.

Dietary interventions were occasionally of benefit (Fig 2); 3 of 8 patients improved symptomatically with a lactose-free diet, and 2 of 10 patients improved symptomatically with a gluten-free diet. High-dose intravenous immunoglobulin (1 g/kg per week for 4 to 6 weeks) had no clear effect. Patient D reported modest symptomatic benefit with Pentaglobin (an immunoglobulin product containing IgA and IgM in addition to IgG; Biotest AG, Dreieich, Germany).

Nitazoxanide (500 mg administered twice daily for a minimum of 4 weeks) was tried in all patients. Patients B and F appeared to clear norovirus after treatment (with symptomatic improvement in patient B, whereas patient F’s symptoms worsened during therapy). However, both later relapsed (after 6 and 14 months, respectively). Patient B restarted nitazoxanide and had negative PCR results for 5 months until relapsing after high-dose steroids and rituximab for hemolytic anemia. Patient G symptomatically improved with nitazoxanide but did not clear norovirus (see Fig E7 in this article’s Online Repository at www.jacionline.org), whereas patient A symptomatically deteriorated; other patients saw no effect.

Seven patients received ribavirin therapy (initial dose, 200 mg in the morning/400 mg in the evening and titrated according to serum levels). Patient E saw symptomatic improvement (see Fig E8 in this article’s Online Repository at www.jacionline.org) and cleared norovirus from stool. However, discontinuation after 11 months of negative results resulted in rapid relapse and was also associated with inflammatory arthritis. Ribavirin reintroduction (with concomitant corticosteroid therapy for arthritis) did not clear norovirus, and the patient had treatment-related anemia. Patients D and J also had anemia while receiving ribavirin. Patient C had an initial virologic response but relapsed despite continuous therapy. She eventually cleared norovirus spontaneously, 2 months after discontinuing ribavirin. Patient J’s symptoms improved with a small viral load decrease before having anemia. Conversely, patient G’s symptoms symptomatically deteriorated on ribavirin, whereas other patients saw no clear effect. Patient D was treated experimentally with favipiravir, as we have described.7

Despite the negative effect of significant immunosuppression, low-dose prednisolone improved patient E’s symptoms (see Fig E8). Other patients receiving low-dose prednisolone have not noted detrimental effects. Patient A with chronic lymphocytic leukemia experienced dramatic symptomatic improvement after receiving ibrutinib to attempt to achieve immune reconstitution.

Cumulatively, more than 1000 days of antibiotics were administered during the study period, with no consistent effect on viral load or gastrointestinal symptoms despite evidence that norovirus cellular invasion requires bacteria.8

In summary, CNI in patients with CVID is associated with almost complete absence of CD27+ B cells (including switched memory B cells), B-cell dysfunction characterized by low expression of CD80 and CXCXR5, a marked increase in numbers of transitional and CD21+ B cells, poor T-cell proliferation, and high PD-1 expression on CD4+ T cells. High numbers of CD21–CXCR5– B cells and PD-1– T cells both imply immunologic “exhaustion.” Diagnosis might be heralded by decreasing lymphocyte counts, which are often driven by iatrogenic immunosuppression (which can also precipitate relapse). The gut mucosa exists intraepithelial cytotoxic T-cell lymphocytosis and, with thorough assessment, invariably demonstrates villous atrophy (unlike recent reports); malabsorption is universal. Cross-transmission within immunodeficiency services appears rare, but we nevertheless advocate strict infection control. Infections last years, with late relapses and high viral diversity. Available treatments are variably effective and require further research.

We acknowledge the staff of the Medical Research Council and UCL/ UCLH Biomedical Research Centre–funded Pathogen Genomics Unit for their expert technical assistance.

Li-An K. Brown, MRCPath4,6
Christopher Rais, PhD4
Ian Clark, MB BS5
Sanudo Roy, PhD
Julianne R. Brown, PhD
Adriana S. Albuquerque, PhD
Smita Y. Patel, PhD, FRCPath6
Joanne Miller, FRCPath6
Mohammed Youssuf Karim, FRCPath4
Samir Derivevic, FRCPath4
Jennifer Moore, MRCPath6
Charlotte A. Williams, BSc4
Juliana Cudini, MSc5
Fernando Moreira, BSc5
Penny Neilid, MD, FRCPath5
Saranjith L. Seneviratne, DPhil, FRCPath6
Sarita Workman, MSc5
Christos Tsoumanakis, PhD, FRCPath6
Claire Atkinson, PhD2
Slobhan O. Burns, PhD2,4
Judith Breuer, MD, FRCPath6
David M. Lowrie, PhD, FRCPath4,5
Suranjith L. Seneviratne, DPhil, FRCPath6
Sarita Workman, MSc5
Christos Tsoumanakis, PhD, FRCPath6
Claire Atkinson, PhD2
Slobhan O. Burns, PhD2,4
Judith Breuer, MD, FRCPath6
David M. Lowrie, PhD, FRCPath4,5
From the Departments of Infectious Diseases, Histopathology, Clinical Immunology, and Gastroenterology, Royal Free London NHS Foundation Trust, London, United
Kingdom; the Department of Microbiology, Whittington Health NHS Trust, London, United Kingdom; the Division of Infection and Immunity, University College London, London, United Kingdom; the Molecular Immunity Unit, Department of Medicine, University of Cambridge, Medical Research Council (MRC)-Laboratory of Molecular Biology, Cambridge, United Kingdom; the Department of Microbiology, Virology and Infection Prevention and Control, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom; the Institute of Immunity and Transplantation, University College London, Royal Free Campus, London, United Kingdom; the Oxford University Hospitals NHS Trust and NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom; Royal Surrey County Hospital NHS Foundation Trust, Egherton Road, Guildford, Surrey, United Kingdom; Pathology, Sidra Medicine, Doha, Qatar; Norfolk and Norwich University Hospital, Norwich, Norfolk, United Kingdom; and St George’s University Hospitals NHS Foundation Trust, London, United Kingdom. E-mail: d.lowe@ucl.ac.uk.

*These authors contributed equally to this work.

At the time of the study, J.R.B. was funded by a National Institute for Health Research (NIHR) doctoral fellowship (grant no NIHR-HCS-D12-03-15). C.R. and S.R. were funded by a Wellcome Trust collaborative award (grant no. 203268/Z/16/Z; to J.R.B.). J.R.B. and D.M.L. receive funding from the NIHR UCL/UCLH Biomedical Research Centre.

Disclosure of potential conflict of interest: S. Workman has received an educational grant from CSL Behring, speakers’ fees from LFB, honorarium from Octapharma, and support to attend conferences from CSL Behring, Grifols, Biotest, Octapharma, LFB, Shire, and the Jeffrey Modell Foundation. S. O. Burns has received speakers’ fees/honoraria from Immunodeficiency Canada/IACHE CSL Behring, and Baxalta US. D. M. Lowe has received travel and subsistence costs for unpaid consultancy work from CSL Behring. The rest of the authors declare that they have no relevant conflicts of interest.

REFERENCES

1. Brown LK, Clark I, Brown JR, Breuer J, Lowe DM. Norovirus infection in primary immune deficiency. Rev Med Virol 2017;23:e1926.

2. Brown JR, Roy S, Rais C, Yara Romero E, Shah D, Williams R, et al. Norovirus whole-genome sequencing by SureSelect target enrichment: a robust and sensitive method. J Clin Microbiol 2016;54:2530-7.

3. Brown JR, Roy S, Tutill H, Williams R, Breuer J. Super-infections and relapses occur in chronic norovirus infections. J Clin Virol 2017;96:44-8.

4. Nei M, Li WH. Mathematical model for studying genetic variation in terms of restriction endonucleases. Proc Natl Acad Sci U S A 1979; 76:5269-73.

5. Depledge DP, Cudini J, Kundu S, Atkinson C, Brown JR, Haque T, et al. High viral diversity and mixed infections in cerebral spinal fluid from cases of varicella zoster virus encephalitis. J Infect Dis 2018;218:1592-601.

6. Bull RA, Eden JS, Rawlinson WD, White PA. Rapid evolution of pandemic noroviruses of the GII.4 lineage. PLoS Pathog 2010;6:e1000831.

7. Ruis C, Brown LK, Roy S, Atkinson C, Williams R, Burns SO, et al. Mutagenesis in norovirus in response to favipiravir treatment. N Engl J Med 2018;379:2173-6.

8. Baldridge MT, Nice TJ, McCune BT, Yokoyama CC, Kambal A, Wheadon M, et al. Commensal microbes and interferon-lambda determine persistence of enteric murine norovirus infection. Science 2015;347:266-9.

9. Rolfes MC, Siaarroon P, Davila Saldana BJ, Dvorak CC, Chapdelaine H, Ferdman RM, et al. Chronic norovirus infection in primary immune deficiency disorders: an international case series. Diagn Microbiol Infect Dis 2019;93:69-73.

Available online August 13, 2019.
https://doi.org/10.1016/j.jaci.2019.07.036